Two Sigma Advisers LP Has $18.37 Million Holdings in iShares Nasdaq Biotechnology ETF (IBB)

Two Sigma Advisers LP raised its position in iShares Nasdaq Biotechnology ETF (NASDAQ:IBB) by 95.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 190,499 shares of the financial services provider’s stock after purchasing an additional 92,900 shares during the quarter. Two Sigma Advisers LP owned about 0.26% of iShares Nasdaq Biotechnology ETF worth $18,370,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently made changes to their positions in the business. Lido Advisors LLC raised its holdings in shares of iShares Nasdaq Biotechnology ETF by 27.6% during the 4th quarter. Lido Advisors LLC now owns 5,430 shares of the financial services provider’s stock valued at $523,000 after purchasing an additional 1,174 shares in the last quarter. Lehman & Derafelo Financial Resources LLC acquired a new stake in shares of iShares Nasdaq Biotechnology ETF during the 4th quarter valued at about $991,000. PRW Wealth Management LLC bought a new position in iShares Nasdaq Biotechnology ETF during the 4th quarter valued at about $278,000. Financial Advisors LLC bought a new position in iShares Nasdaq Biotechnology ETF during the 4th quarter valued at about $233,000. Finally, Genesee Capital Advisors LLC bought a new position in iShares Nasdaq Biotechnology ETF during the 4th quarter valued at about $42,000. Institutional investors own 65.05% of the company’s stock.

IBB opened at $108.17 on Monday. iShares Nasdaq Biotechnology ETF has a fifty-two week low of $89.01 and a fifty-two week high of $122.97.



ILLEGAL ACTIVITY WARNING: “Two Sigma Advisers LP Has $18.37 Million Holdings in iShares Nasdaq Biotechnology ETF (IBB)” was first posted by Dakota Financial News and is the property of of Dakota Financial News. If you are accessing this piece of content on another domain, it was illegally copied and republished in violation of United States and international trademark and copyright law. The correct version of this piece of content can be read at https://dakotafinancialnews.com/2019/03/25/two-sigma-advisers-lp-has-18-37-million-holdings-in-ishares-nasdaq-biotechnology-etf-ibb.html.

iShares Nasdaq Biotechnology ETF Company Profile

iShares Nasdaq Biotechnology ETF (the Fund), formerly iShares Nasdaq Biotechnology Index Fund, is an exchange-traded fund (ETF). The Fund seeks investment results that correspond generally to the price and yield performance of the NASDAQ Biotechnology Index (the Index). The Index contains securities of NASDAQ listed companies that are classified according to the Industry Classification Benchmark as either biotechnology or pharmaceuticals, which also meet other eligibility criteria determined by NASDAQ.

Read More: How is net asset value different from market price?

Want to see what other hedge funds are holding IBB? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB).

Institutional Ownership by Quarter for iShares Nasdaq Biotechnology ETF (NASDAQ:IBB)

Receive News & Ratings for iShares Nasdaq Biotechnology ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Nasdaq Biotechnology ETF and related companies with MarketBeat.com's FREE daily email newsletter.